Tech Company Financing Transactions
Dewpoint Therapeutics Funding Round
On 2/12/2022, Dewpoint Therapeutics raised $150 million in Series C funding from SoftBank Vision Fund, 3E Bioventures and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
2/12/2022
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance multiple pipeline programs through to IND and further invest in Dewpoint's fully integrated, multi-component biology platform as well as its artificial intelligence-driven data science platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6 Tide St. 300
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Dewpoint is translating new insights into biomolecular condensates and cellular function to uncover treatments for the toughest diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amir Nashat
Chief Operating Officer
Bruce Beutel
Chief Scientific Officer
Mark Murcko
Founder
Anthony Hyman
Founder
Richard Young
Vice President
William Chen
Vice President
Peter Dandliker
Vice President
Stephen Hale
Vice President
Alexander Szewczak
Vice President
Rebecca Zacks
VP - Bus. Development
Scott Peterson
VP - Human Resources
Holly Abernethy
VP - R & D
Ann Kwong
Browse more venture capital transactions:
Prev: 2/12/2022: RareCircles venture capital transaction
Next: 2/12/2022: Getlabs venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs